TESARO (NASDAQ: TSRO) recently received a number of ratings updates from brokerages and research firms:

  • 11/20/2018 – TESARO was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 11/19/2018 – TESARO had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $68.00 price target on the stock. They wrote, “: 12-month PT of $68 on shares of TSRO. Bloomberg reported last week that Tesaro was exploring a sale. We think that the company remains undervalued based on 1) PARP inhibitor potential in first-line ovarian cancer and 2) potential with its immuno-oncology platform (licensed from AnaptysBio, ANAB, OW, covered by Eliana Merle) that is beginning to shape up with data readouts. We also believe that it can take time for deals to emerge, so we think that this press article could be a way of garnering interest for the company beyond potentially initial interest. In the past, we think that this company had been a potential takeout interest from biopharmaceutical companies.””
  • 11/13/2018 – TESARO had its “outperform” rating reaffirmed by analysts at Wedbush.
  • 11/12/2018 – TESARO had its price target lowered by analysts at Jefferies Financial Group Inc from $38.00 to $25.00. They now have a “hold” rating on the stock.
  • 11/11/2018 – TESARO was given a new $83.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 11/9/2018 – TESARO had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $68.00 price target on the stock. They wrote, “. We reiterate our Overweight rating and 12-month price target of $68. This morning, TSRO presented an updated GARNET study (anti- PD1 TSR-042) results in 2nd line NSCLC patients and also initial safety results from the anti-LAG-3 agent TSR-033 in poster presentations at the ongoing SITC annual meeting. Overall, the GARNET data reported improved response rates in a larger cohort size of 2nd line NSCLC patients and TSR-042 activity profile in this setting looks compelling so far. The anti-LAG-3 initial safety data were largely in- line with the published abstract.””
  • 11/2/2018 – TESARO had its price target raised by analysts at Wedbush from $60.00 to $67.00. They now have an “outperform” rating on the stock.
  • 11/2/2018 – TESARO had its price target raised by analysts at Bank of America Corp from $38.00 to $39.00. They now have a “neutral” rating on the stock.
  • 11/2/2018 – TESARO had its “hold” rating reaffirmed by analysts at Cowen Inc. They now have a $38.00 price target on the stock.
  • 11/2/2018 – TESARO had its “buy” rating reaffirmed by analysts at Cann. They now have a $83.00 price target on the stock. They wrote, “Tesaro released Q3 2018 results today with Zejula sales of $63.2 million, which exceeded our estimated $60.1 million by 5.1%, and consensus of $60.8 million by 4%. Better than estimated sales resulted from unit demand increases and strong growth outside the US. Total revenue of $64.4 million was lower than our estimated $68.0 million due to Varubi collaboration revenue of $0.4 million, which was lower than our estimated $7.0 million, and consensus of $2.8 million. Total operating expenses of $202.6 million were 13.7% higher than our estimated $178.2 million, due to lower than estimated R&D expense. Tesaro lost $2.49 per share compared to our estimated loss per share of $2.19 and consensus loss per share of $2.55.””
  • 11/1/2018 – TESARO was given a new $83.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 10/25/2018 – TESARO was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 10/24/2018 – TESARO was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 10/23/2018 – TESARO was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “TESARO's drug, Zejula has performed well since its approval in early 2017, gaining lead in U.S. ovarian cancer market share in the PARP inhibitor segment. The drug also has bright prospects, given the tremendous demand for PARP inhibitors. Moreover, collaborations with several large pharma companies for the development of Zejula generates a cash flow stream for TESARO and enables sharing of R&D costs. TESARO’s efforts for label expansion of Zejula are also encouraging. However, TESARO is heavily dependent on Zejula for growth, which concerns us. Meanwhile, competition in the PARP inhibitor segment is rising with two other approved drugs and several companies developing their candidates. TESARO’s shares have underperformed the industry so far this year. Loss estimates have widened ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters.”
  • 10/22/2018 – TESARO had its price target raised by analysts at Cantor Fitzgerald from $57.00 to $68.00. They now have a “positive” rating on the stock.
  • 10/22/2018 – TESARO had its “hold” rating reaffirmed by analysts at Cowen Inc. They now have a $38.00 price target on the stock.
  • 10/19/2018 – TESARO was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 10/12/2018 – TESARO was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 10/5/2018 – TESARO was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 10/1/2018 – TESARO is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $57.00 price target on the stock. They wrote, “We hosted Tesaro management (Lonnie Moulder, CEO and Mary Lynne Hedley, President & COO) at our investor dinner at Cantor Global Healthcare Conference. We think that management remain upbeat around the Zejula launch and progress in the company’s IO pipeline programs. Our thesis (click here) continues to be that expectations remain low for the company, and we see many events and milestones that remain not appreciated at the current valuation. Our dinner discussions were almost evenly split between the Zejula opportunity and IO programs.””
  • 9/28/2018 – TESARO was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 9/24/2018 – TESARO is now covered by analysts at Leerink Swann. They set an “outperform” rating and a $48.00 price target on the stock.

Shares of NASDAQ:TSRO opened at $42.48 on Wednesday. TESARO Inc has a 12-month low of $23.41 and a 12-month high of $87.93. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of -4.63 and a beta of 1.35. The company has a debt-to-equity ratio of 3.74, a current ratio of 3.40 and a quick ratio of 2.83.

TESARO (NASDAQ:TSRO) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($2.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.62) by $0.13. TESARO had a negative return on equity of 1,209.72% and a negative net margin of 295.67%. The company had revenue of $64.40 million during the quarter, compared to the consensus estimate of $71.84 million. During the same period in the previous year, the company posted ($0.47) earnings per share. TESARO’s revenue for the quarter was down 54.9% on a year-over-year basis. On average, sell-side analysts anticipate that TESARO Inc will post -10.87 EPS for the current year.

Large investors have recently made changes to their positions in the business. US Bancorp DE lifted its holdings in TESARO by 163.5% in the third quarter. US Bancorp DE now owns 3,940 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 2,445 shares during the period. Skylands Capital LLC acquired a new position in TESARO in the second quarter valued at approximately $182,000. New Jersey Better Educational Savings Trust acquired a new position in TESARO in the third quarter valued at approximately $234,000. Janney Montgomery Scott LLC acquired a new position in TESARO in the second quarter valued at approximately $257,000. Finally, Pacer Advisors Inc. acquired a new position in TESARO in the third quarter valued at approximately $273,000.

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Read More: Why do companies engage in swaps?

Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.